Clinical Trials Directory

Trials / Sponsors / Humacyte, Inc.

Humacyte, Inc.

Industry · 12 registered clinical trials — 1 currently recruiting.

StatusTrialPhaseStarted
RecruitingTo Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requir
End Stage Renal Disease (ESRD)
Phase 32023-09-07
CompletedAn Observational Study to Evaluate the Safety and Efficacy of Humacyte's HAV for Arterial Replacement or Recon
Trauma, Trauma Injury, Trauma, Multiple
—2023-05-01
CompletedSafety and Efficacy Assessment of HAV in Patients Needing Vascular Access for Dialysis
Renal Failure, End Stage Renal Disease, Vascular Access
Phase 22019-11-12
Active Not RecruitingHumacyte Human Acellular Vessel (HAV) in Patients With Vascular Trauma
Trauma, Vascular System Injury
Phase 2 / Phase 32018-09-01
CompletedComparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis
Renal Failure, End Stage Renal Disease, Hemodialysis
Phase 32017-09-29
CompletedHumacyte's HAV for Femoro-Popliteal Bypass in Patients With PAD
Peripheral Artery Disease
Phase 22016-12-20
CompletedComparison of the Human Acellular Vessel (HAV) With ePTFE Grafts as Conduits for Hemodialysis
Renal Failure, End Stage Renal Disease, Hemodialysis
Phase 32016-05-24
CompletedEvaluation of the Safety and Efficacy of a Vascular Prosthesis as an Above-Knee Bypass Graft in Patients With
Peripheral Arterial Disease, Peripheral Vascular Disease
N/A2013-10-10
CompletedSafety and Efficacy of a Vascular Prosthesis for Hemodialysis Access in Patients With End-Stage Renal Disease
End-stage Renal Disease, Kidney Failure, Chronic
Phase 12013-05-23
CompletedEvaluation of the Safety and Efficacy of a Vascular Prosthesis for Hemodialysis Access in Patients With ESRD
End-stage Renal Disease, Kidney Failure, Chronic
N/A2012-11-22
Approved For MarketingIndividual Patient Expanded Access for Acellular Tissue Engineered Vessel (ATEV) for Vascular System Injuries
Vascular System Injuries
——
Temporarily Not AvailableIndividual Patient Expanded Access for Acellular Tissue Engineered Vessel (ATEV) for Vascular Disease and Dial
Vascular Diseases, End Stage Renal Disease on Dialysis
——